See the DrugPatentWatch profile for Metoprolol
When did Metoprolol first hit the market?
Metoprolol, a selective β‑1 blocker, was introduced in the early 1970s. The first commercial product, a 12.5 mg tablet, was launched by Pfizer (then part of Smith, Kline & French) in the United Kingdom in 1974, and the U.S. Food and Drug Administration approved the drug the following year for hypertension [1].
How did its indications expand over the years?
After its hypertension approval, metoprolol became a frontline treatment for angina pectoris in the late 1970s. In the 1980s the drug was added to the armamentarium for acute myocardial infarction and for the prevention of recurrent cardiac events. The 1990s saw approval for heart‑failure management and for prophylaxis against stroke in patients with atrial fibrillation. By the early 2000s it was widely used as a standard therapy in chronic heart disease and as a first‑line agent for hypertension in many treatment guidelines.
When did the original patent expire, and what happened then?
The original U.S. patent on metoprolol, granted in the late 1960s, expired in the early 1990s. Generic manufacturers began filing applications in the mid‑1990s, and the first generic metoprolol tablets entered the U.S. market in 1998. The availability of low‑cost generics markedly increased its prescription volume throughout the 2000s [2].
Who was the first to market Metoprolol, and which companies followed?
Pfizer was the pioneer, marketing the drug under the brand name Toprol. Other companies—such as Sanofi‑Genzyme, Teva, and Mylan—entered the market with generic formulations after the patent expired, offering names like Toprol‑XL (extended‑release) and Metoprolol succinate (once‑daily dosing).
What major clinical trials shaped its use?
The first pivotal study, published in 1979, demonstrated metoprolol’s efficacy in reducing blood pressure and improving survival after myocardial infarction. Subsequent trials in the 1990s, notably the MERIT‑Heart study (1999), confirmed the benefit of metoprolol in heart‑failure patients, cementing its role in chronic heart‑failure guidelines.
When did Metoprolol become a staple in hypertension guidelines?
The American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines incorporated metoprolol as a first‑line therapy for patients with left ventricular hypertrophy and for those with comorbid cardiac conditions as early as 2003. Its inclusion remained unchanged in later guideline updates.
Why did generic manufacturers focus on extended‑release formulations?
Extended‑release metoprolol (e.g., Toprol‑XL) was developed to improve patient adherence by allowing once‑daily dosing. The first extended‑release formulation was approved in 2001, and by 2006 it dominated the market for chronic hypertension and heart‑failure therapy [3].
How does Metoprolol’s patent history influence current pricing?
Because the original patent expired decades ago, the drug’s price has remained low compared to newer cardiovascular agents. Generic versions cost a fraction of the brand‑name price, contributing to its high prescription rates worldwide. Recent biosimilar developments have not affected metoprolol due to its small‑molecule status.
What does the future hold for Metoprolol?
Metoprolol continues to be a foundational drug in cardiology. While newer β‑blockers with improved side‑effect profiles exist, metoprolol remains preferred for its proven track record, extensive safety data, and cost advantage. Ongoing research focuses on optimizing dosing regimens and exploring combination therapy with other cardiovascular agents.
Sources
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/